Susie Adams, PhD, RN, PMHNP, FAANP
Professor and Director
Psychiatric-Mental Health Nurse Practitioner Program
Vanderbilt University School of Nursing
1.5 contact hour of continuing education (which includes 0.25 hours of pharmacology)
THIS PROGRAM WAS ORIGINALLY PRESENTED AS AN AANP LIVE GROUP LECTURE SERIES (GLS) BEGINNING FEBRUARY 3, 2011. IF YOU RECEIVED CREDIT FOR PARTICIPATING IN THE GLS, YOU ARE NOT ELIGIBLE TO RECEIVE CREDIT FOR THIS ONLINE ACTIVITY.
Bipolar disorder is the sixth leading cause of disability worldwide with a lifetime prevalence of 3.7% to 3.9%. Individuals with bipolar disorder experience episodes of mood elevation and depression, leading to significant reductions in functional status and quality of life. Along with marked functional and psychosocial impairment, bipolar disorder is also associated with a high prevalence of medical and psychiatric comorbidity, and a lifetime suicide risk of 15%.
Bipolar disorder is not easily diagnosed in many patients who present with symptoms of depression. As a result, many patients are improperly treated. Even patients appropriately diagnosed with bipolar disorder are not routinely receiving therapy that is tailored based on the severity of their disease, the presence of co-morbidities, and other individual factors.
Nurse practitioners play a vital role in improving the diagnosis and management of patients with bipolar disorder. They are uniquely positioned to fulfill the critical role of assessing and diagnosing bipolar disorder, recommending treatment plans, and educating and motivating patients to adhere to treatment regimens so they can experience the maximum benefit from their therapy. Program Developer/Facilitator
Developed by the American Association of Nurse Practitioners in cooperation with
MCM Education Target Audience
This program was developed for nurse practitioners.
Upon completion of this educational activity, the participant should be able to:
Outline the diagnostic criteria and categories for bipolar disorders.
Explain how to differentiate bipolar disorder from common comorbidities and other mental health disorders.
Review recent clinical data regarding ways to individualize the management of patients with bipolar disorder.
Describe considerations for bipolar disorder management strategies based on the presence of different patient characteristics and comorbidities.
Dr. Adams has no conflicts of interest to disclose.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program. Credit Statements
This program is approved for 1.5 contact hour of continuing education (which includes 0.25 hours of pharmacology) by the American Association of Nurse Practitioners. Program ID 1109305.
This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards.
Commercial Support Statements
This activity is supported through an educational grant from AstraZeneca.
COMPLETING THE POST TEST AND EVALUATION:
When you return to the AANP CE Center, login and find the program you wish to complete. On the programís content page you can go directly to Start Post-Test at the bottom of the page. When you have successfully completed the online post-test you will be instructed to complete the online evaluation and then receive your certificate.
If you do not have a registration (email and password) with AANP, you will be asked to register: MyAANP. Complete the short profile and create your password to continue in the CE Center. Please contact Stormy Causey, CE Coordinator, at CECenter@aanp.org with any questions.
The opinions expressed in this presentation are those of the speaker and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, the American Academy of Nurse Practitioners, or AstraZeneca.